Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson’s Disease
Targeted therapy of Parkinson’s disease is an important challenge because of the blood–brain barrier limitation. Here, we propose a natural killer cell membrane biomimetic nanocomplex (named BLIPO-CUR) delivered via the meningeal lymphatic vessel (MLV) route to further the therapeutic efficacy of Pa...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association for the Advancement of Science (AAAS)
2023-01-01
|
| Series: | Research |
| Online Access: | https://spj.science.org/doi/10.34133/research.0030 |
| _version_ | 1827331732834091008 |
|---|---|
| author | Jing Liu Duyang Gao Dehong Hu Siyi Lan Yu Liu Hairong Zheng Zhen Yuan Zonghai Sheng |
| author_facet | Jing Liu Duyang Gao Dehong Hu Siyi Lan Yu Liu Hairong Zheng Zhen Yuan Zonghai Sheng |
| author_sort | Jing Liu |
| collection | DOAJ |
| description | Targeted therapy of Parkinson’s disease is an important challenge because of the blood–brain barrier limitation. Here, we propose a natural killer cell membrane biomimetic nanocomplex (named BLIPO-CUR) delivered via the meningeal lymphatic vessel (MLV) route to further the therapeutic efficacy of Parkinson’s disease. The membrane incorporation enables BLIPO-CUR to target the damaged neurons, thus improving their therapeutic efficacy through clearing reactive oxygen species, suppressing the aggregation of α-synuclein, and inhibiting the spread of excess α-synuclein species. Compared with the conventional intravenous injection, this MLV administration can enhance the delivered efficiency of curcumin into the brain by ~20 folds. The MLV route administration of BLIPO-CUR enhances the treatment efficacy of Parkinson’s disease in mouse models by improving their movement disorders and reversing neuron death. Our findings highlight the great potential of MLV route administration used as targeted delivery of drugs to the brain, holding a great promise for neurodegenerative disease therapy. |
| first_indexed | 2024-03-07T16:44:34Z |
| format | Article |
| id | doaj.art-a9866377bbcd47efbc1bb9be5617a5cc |
| institution | Directory Open Access Journal |
| issn | 2639-5274 |
| language | English |
| last_indexed | 2024-03-07T16:44:34Z |
| publishDate | 2023-01-01 |
| publisher | American Association for the Advancement of Science (AAAS) |
| record_format | Article |
| series | Research |
| spelling | doaj.art-a9866377bbcd47efbc1bb9be5617a5cc2024-03-03T06:58:42ZengAmerican Association for the Advancement of Science (AAAS)Research2639-52742023-01-01610.34133/research.0030Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson’s DiseaseJing Liu0Duyang Gao1Dehong Hu2Siyi Lan3Yu Liu4Hairong Zheng5Zhen Yuan6Zonghai Sheng7Faculty of Health Sciences, Centre for Cognitive and Brian Sciences, University of Macau, Macau SAR 999078, P. R. China.Paul C. Lauterbur Research Center for Biomedical Imaging, Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province, Shenzhen Key Laboratory of Ultrasound Imaging and Therapy, CAS Key Laboratory of Health Informatics, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.Paul C. Lauterbur Research Center for Biomedical Imaging, Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province, Shenzhen Key Laboratory of Ultrasound Imaging and Therapy, CAS Key Laboratory of Health Informatics, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.Paul C. Lauterbur Research Center for Biomedical Imaging, Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province, Shenzhen Key Laboratory of Ultrasound Imaging and Therapy, CAS Key Laboratory of Health Informatics, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.Paul C. Lauterbur Research Center for Biomedical Imaging, Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province, Shenzhen Key Laboratory of Ultrasound Imaging and Therapy, CAS Key Laboratory of Health Informatics, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.Paul C. Lauterbur Research Center for Biomedical Imaging, Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province, Shenzhen Key Laboratory of Ultrasound Imaging and Therapy, CAS Key Laboratory of Health Informatics, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.Faculty of Health Sciences, Centre for Cognitive and Brian Sciences, University of Macau, Macau SAR 999078, P. R. China.Paul C. Lauterbur Research Center for Biomedical Imaging, Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province, Shenzhen Key Laboratory of Ultrasound Imaging and Therapy, CAS Key Laboratory of Health Informatics, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.Targeted therapy of Parkinson’s disease is an important challenge because of the blood–brain barrier limitation. Here, we propose a natural killer cell membrane biomimetic nanocomplex (named BLIPO-CUR) delivered via the meningeal lymphatic vessel (MLV) route to further the therapeutic efficacy of Parkinson’s disease. The membrane incorporation enables BLIPO-CUR to target the damaged neurons, thus improving their therapeutic efficacy through clearing reactive oxygen species, suppressing the aggregation of α-synuclein, and inhibiting the spread of excess α-synuclein species. Compared with the conventional intravenous injection, this MLV administration can enhance the delivered efficiency of curcumin into the brain by ~20 folds. The MLV route administration of BLIPO-CUR enhances the treatment efficacy of Parkinson’s disease in mouse models by improving their movement disorders and reversing neuron death. Our findings highlight the great potential of MLV route administration used as targeted delivery of drugs to the brain, holding a great promise for neurodegenerative disease therapy.https://spj.science.org/doi/10.34133/research.0030 |
| spellingShingle | Jing Liu Duyang Gao Dehong Hu Siyi Lan Yu Liu Hairong Zheng Zhen Yuan Zonghai Sheng Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson’s Disease Research |
| title | Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson’s Disease |
| title_full | Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson’s Disease |
| title_fullStr | Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson’s Disease |
| title_full_unstemmed | Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson’s Disease |
| title_short | Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson’s Disease |
| title_sort | delivery of biomimetic liposomes via meningeal lymphatic vessels route for targeted therapy of parkinson s disease |
| url | https://spj.science.org/doi/10.34133/research.0030 |
| work_keys_str_mv | AT jingliu deliveryofbiomimeticliposomesviameningeallymphaticvesselsroutefortargetedtherapyofparkinsonsdisease AT duyanggao deliveryofbiomimeticliposomesviameningeallymphaticvesselsroutefortargetedtherapyofparkinsonsdisease AT dehonghu deliveryofbiomimeticliposomesviameningeallymphaticvesselsroutefortargetedtherapyofparkinsonsdisease AT siyilan deliveryofbiomimeticliposomesviameningeallymphaticvesselsroutefortargetedtherapyofparkinsonsdisease AT yuliu deliveryofbiomimeticliposomesviameningeallymphaticvesselsroutefortargetedtherapyofparkinsonsdisease AT hairongzheng deliveryofbiomimeticliposomesviameningeallymphaticvesselsroutefortargetedtherapyofparkinsonsdisease AT zhenyuan deliveryofbiomimeticliposomesviameningeallymphaticvesselsroutefortargetedtherapyofparkinsonsdisease AT zonghaisheng deliveryofbiomimeticliposomesviameningeallymphaticvesselsroutefortargetedtherapyofparkinsonsdisease |